Sector News

Hot buyout target Stada rolls out cost-cutting measures

March 17, 2017
Life sciences

The bidding war for Germany’s Stada is heating up, with private equity firms, Chinese drugmakers and others rumored to be in the mix. But their offers so far aren’t high enough to woo the company, which is rolling out cost-cutting measures and new guidance in an attempt to bring in larger bids.

Friday, the company upped its 2019 adjusted EBITDA target, taking it from a range of €570 million to €590 million ($612.8 million to $634.3 million) from a previously predicted €510 million ($548.3 million). It also brought its sales target to between €2.65 billion and €2.7 billion ($2.85 billion to $2.9 billion) from the €2.6 billion ($2.8 billion) it earlier outlined, and it laid out changes that would help streamline its processes and squeeze out cost savings.

Among them: Optimizing its supply chain management and procurement process and organization, from which it expects “significant savings potential,” the company said in a statement. It’s also looking at longer-term measures to bring its internal production costs down a notch, including the rollout of a global production system.

The revamped forecasts and cost-cutting moves are part of an effort to bring in bigger buyout offers from the group of interested parties eyeing the German generics maker. That group for sure includes PE outfits Advent International—which has already bid—and Cinven. But reportedly drugmakers such as Shanghai Pharmaceuticals also are interested.

Why all the attention coming Stada’s way? The potential for even further cost-cutting and earnings-boosting. Stada’s three-year average operating profit margin currently sits at 11%, Bloomberg notes, ranking it among the lowest worldwide for generics players. Streamlining manufacturing, breaking up the business and laying off employees could all be options for buyers trying to wring out savings.

And for PE players, teaming up with drugmakers on bids—as some of Stada’s suitors are reportedly looking to do—could enhance their cost-cutting options even further.

Stada, though, isn’t going to give them the chance unless the price is right. Earlier this week, company chairman Carl-Ferdinand Oetker, the leader of a supervisory board committee to oversee the bidding process, urged execs to make edits that would help bolster Stada’s profit guidance, Bloomberg reports. His committee also refused to approve additional due diligence from interested bidding groups, and earlier this week execs canceled planned presentations to them accordingly.

“The indicative bids do not yet reflect the fundamental value of Stada. Thus, the company, for the time being, wants to provide the bidders the opportunity to increase their offers,” the company said in a Thursday statement on the negotiation delay.

So far, Advent has pledged €58 ($62.36) per share, but some industry watches expect that number to climb as high as €60 ($64.51).

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach